share_log

Heart Test Laboratories | 10-Q: Quarterly report

Heart Test Laboratories | 10-Q: Quarterly report

Heart Test Laboratories | 10-Q：季度报表
SEC announcement ·  03/14 16:14
Moomoo AI 已提取核心信息
Heart Test Laboratories, a medical technology company, has not provided specific financial performance metrics such as revenue, operating profit, net profit, or diluted earnings per share in its latest quarterly report. However, the company has disclosed stock-based compensation for stock options, which increased from $149,153 in the nine months ended January 31, 2023, to $326,578 in the same period in 2024. Deferred tax assets have also been reported, with a net operating loss carryforwards of approximately $52 million as of January 31, 2024, up from $46 million the previous year. The company has entered into significant business development agreements, including a multi-year collaboration with Rutgers University and multiple definitive license agreements with Mount Sinai for AI cardiovascular algorithms. Heart Test Laboratories plans to submit a 510(k) FDA submission for its MyoVista device and is aiming for clearance within the 2024 calendar year. The company has also received patent allowances in various regions and has entered into financial agreements to support its operations, including an Equity Distribution Agreement with Maxim Group LLC.
Heart Test Laboratories, a medical technology company, has not provided specific financial performance metrics such as revenue, operating profit, net profit, or diluted earnings per share in its latest quarterly report. However, the company has disclosed stock-based compensation for stock options, which increased from $149,153 in the nine months ended January 31, 2023, to $326,578 in the same period in 2024. Deferred tax assets have also been reported, with a net operating loss carryforwards of approximately $52 million as of January 31, 2024, up from $46 million the previous year. The company has entered into significant business development agreements, including a multi-year collaboration with Rutgers University and multiple definitive license agreements with Mount Sinai for AI cardiovascular algorithms. Heart Test Laboratories plans to submit a 510(k) FDA submission for its MyoVista device and is aiming for clearance within the 2024 calendar year. The company has also received patent allowances in various regions and has entered into financial agreements to support its operations, including an Equity Distribution Agreement with Maxim Group LLC.
医疗技术公司Heart Test Laboratories在其最新的季度报告中没有提供具体的财务业绩指标，例如收入、营业利润、净利润或摊薄后的每股收益。但是，该公司披露了股票期权的股票薪酬，该薪酬从截至2023年1月31日的九个月的149,153美元增加到2024年同期的326,578美元。还报告了递延所得税资产，截至2024年1月31日，净营业亏损结转额约为5200万美元，高于去年的4600万美元。该公司已经签订了重要的业务开发协议，包括与罗格斯大学的多年合作，以及与西奈山签署的多项人工智能心血管算法的最终许可协议。心脏测试实验室计划为其MyoVista设备提交美国食品药品管理局的510（k）份申请，并计划在2024日历年内获得批准。该公司还获得了各个地区的专利补贴，并签订了财务协议以支持其运营，包括与Maxim Group LLC签订的股权分配协议。
医疗技术公司Heart Test Laboratories在其最新的季度报告中没有提供具体的财务业绩指标，例如收入、营业利润、净利润或摊薄后的每股收益。但是，该公司披露了股票期权的股票薪酬，该薪酬从截至2023年1月31日的九个月的149,153美元增加到2024年同期的326,578美元。还报告了递延所得税资产，截至2024年1月31日，净营业亏损结转额约为5200万美元，高于去年的4600万美元。该公司已经签订了重要的业务开发协议，包括与罗格斯大学的多年合作，以及与西奈山签署的多项人工智能心血管算法的最终许可协议。心脏测试实验室计划为其MyoVista设备提交美国食品药品管理局的510（k）份申请，并计划在2024日历年内获得批准。该公司还获得了各个地区的专利补贴，并签订了财务协议以支持其运营，包括与Maxim Group LLC签订的股权分配协议。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息